Concepedia

Publication | Open Access

Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

DOIFull Paper Access

380

Citations

21

References

2023

Year

Karim Fizazi, Josep M. Piulats, M. Neil Reaume, Peter Ostler, Ray McDermott, Joel Roger Gingerich, Elias Pintus, Srikala S. Sridhar, Richard Bambury, Urban Emmenegger,
New England Journal of Medicine

Abstract

The duration of imaging-based progression-free survival was significantly longer with rucaparib than with a control medication among patients who had metastatic, castration-resistant prostate cancer with a <i>BRCA</i> alteration. (Funded by Clovis Oncology; TRITON3 ClinicalTrials.gov number, NCT02975934.).

References

YearCitations

Page 1